stockportfolio.pro
Enliven Therapeutics, Inc. (ELVN)
Healthcare · Biotechnology · NasdaqGS
Enliven Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-23.46M | $-41.36M | $-51.38M | $-37.66M | $-71.58M | $-89.02M | $-103.69M |
| Net margin | — | — | — | — | — | — | — |
Source: Enliven Therapeutics, Inc. SEC filings (10-K).
Explore 7 years of Enliven Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ELVN in your portfolio →
Enliven Therapeutics, Inc. financial history by metric
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc. — frequently asked questions
What is Enliven Therapeutics, Inc.'s revenue?
Enliven Therapeutics, Inc. (ELVN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Enliven Therapeutics, Inc. profitable?
No — ELVN reported a net loss of $-103.69M in fiscal 2025.
What is ELVN's P/E ratio?
Enliven Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Enliven Therapeutics, Inc. have?
As of fiscal year 2025, ELVN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Enliven Therapeutics, Inc.'s market cap?
Enliven Therapeutics, Inc. (ELVN) has a market capitalization of about $2.51B, based on the latest data in our nightly-refreshed cache.
When does Enliven Therapeutics, Inc.'s fiscal year end?
ELVN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Enliven Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.